Transplant Outcomes in Bone Marrow Failure Syndromes and Hemoglobinopathies

Margaret L. MacMillan, Mark C. Walters, Eliane Gluckman

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure remains a significant problem, UCB transplantation (UCBT) using the optimal conditioning regimen can be a salvage treatment for patients without a suitable BM donor and warrants evaluation in further prospective studies.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalSeminars in hematology
Volume47
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Dive into the research topics of 'Transplant Outcomes in Bone Marrow Failure Syndromes and Hemoglobinopathies'. Together they form a unique fingerprint.

Cite this